Biocon Profit Surges on Strong YoY Growth, but Momentum Slows Sequentially
Biocon's first-quarter profit jumped over 53% from a year ago, though revenue and earnings softened compared to the previous quarter.
Biocon reported a strong year-on-year profit increase of 53.4% for Q1 FY27. However, both revenue and profit declined sequentially from the previous quarter.
Biocon's first-quarter earnings for FY27 present a mixed picture, with robust year-on-year growth tempered by a sequential slowdown. Profit after tax surged 53.4% from the same period last year to ₹136.8 crore, supported by a 10% rise in revenue to ₹4,336 crore. However, compared to the strong fourth quarter of FY26, both revenue and profit retreated, declining 4.0% and 31.1% respectively.
The quarterly trajectory highlights a business emerging from volatility. The company's net profit margin improved to 3.2% in Q1 FY27, up 90 basis points from 2.3% a year ago, indicating better profitability on its sales. Yet, this margin is down from the 4.4% achieved in the prior quarter, reflecting the sequential earnings pressure.
A look at the last five quarters shows the progress and challenges:
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin
| Metric | CurrentQ1 FY27 | PreviousQ4 FY26 | Same quarter LYQ1 FY26 |
|---|---|---|---|
| Revenue (₹ Cr) | 4,336.0YoY +10% | 4,516.6 | 3,941.9 |
| Profit (₹ Cr) | 136.8YoY +53% | 198.6 | 89.2 |
| Net Profit Margin | 3.2%YoY +39% | 4.4% | 2.3% |
This performance has unfolded against a backdrop of strong long-term shareholder returns, with the stock delivering a 63.8% absolute return over the past three years. The key question for the coming quarters is whether Biocon can stabilize its sequential performance while maintaining its improved year-on-year profitability.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.